A new trading day began on Tuesday, with Arcutis Biotherapeutics Inc (NASDAQ: ARQT) stock price down -1.04% from the previous day of trading, before settling in for the closing price of $13.40. ARQT’s price has ranged from $7.64 to $17.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 52.31%. With a float of $104.86 million, this company’s outstanding shares have now reached $119.14 million.
Let’s determine the extent of company efficiency that accounts for 342 employees. In terms of profitability, gross margin is 88.39%, operating margin of -57.0%, and the pretax margin is -60.67%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.04%, while institutional ownership is 98.78%. The most recent insider transaction that took place on Jun 13 ’25, was worth 34,610. In this transaction Director of this company bought 2,646 shares at a rate of $13.08, taking the stock ownership to the 27,448 shares. Before that another transaction happened on Jun 04 ’25, when Company’s Director bought 1,890 for $13.32, making the entire transaction worth $25,177. This insider now owns 24,424 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.31% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Here are Arcutis Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach 0.20 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Looking closely at Arcutis Biotherapeutics Inc (NASDAQ: ARQT), its last 5-days average volume was 2.06 million, which is a drop from its year-to-date volume of 2.27 million. As of the previous 9 days, the stock’s Stochastic %D was 30.20%. Additionally, its Average True Range was 0.71.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 32.18%, which indicates a significant increase from 25.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.04% in the past 14 days, which was lower than the 69.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.88, while its 200-day Moving Average is $12.64. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $13.38. Second resistance stands at $13.51. The third major resistance level sits at $13.71. If the price goes on to break the first support level at $13.05, it is likely to go to the next support level at $12.85. Should the price break the second support level, the third support level stands at $12.72.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
With a market capitalization of 1.58 billion, the company has a total of 119,202K Shares Outstanding. Currently, annual sales are 196,540 K while annual income is -140,040 K. The company’s previous quarter sales were 65,850 K while its latest quarter income was -25,060 K.
